This page collects WhisperX intelligence signals tagged #KRAS. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
A Phase 3 trial for advanced pancreatic cancer has delivered a result so significant it could redefine the treatment landscape. Revolution Medicines' experimental oral drug, daraxonrasib, nearly doubled median overall survival compared to standard chemotherapy, extending life from 6.7 months to 13.2 months. This stark ...
The American Association for Cancer Research (AACR) annual meeting in San Diego is being dominated by promising new data for KRAS-targeting therapies, with Revolution Medicines' lead drug, RMC-6236, delivering another round of compelling results. The findings solidify the compound's position at the forefront of one of ...
The American Association for Cancer Research (AACR) annual meeting has been dominated by a single, stunning data release. Biotechnology firm Revolution Medicines presented results showing its experimental KRAS-targeting drug, daraxonrasib, more than doubled survival in second-line pancreatic cancer patients compared to...
Revolution Medicines is not just riding high on the clinical success of its lead KRAS inhibitor; it's already laying the groundwork for what comes next. At the American Association for Cancer Research annual meeting, the company solidified daraxonrasib's status as a potential game-changer in advanced pancreatic cancer,...